Posted on:
Dec 12, 2013 04:28AM
- edited
Oct 5, 2014 07:45AM
by
moderators
M
Philadelphia
Joined:
Sep 2007
Posts:
25,108
Latest activity:
May 19, 2022
Posted on:
Dec 12, 2013 04:28AM
- edited
Oct 5, 2014 07:45AM
by
moderators
moderators
wrote:
Please go here to read about and listen to all our Podcasts! We will also be posting podcasts below as they air.
Note: Podcasts will be available in transcript form about 24 - 48 hours after the Podcasts have aired.
Log in to post a reply
M
moderators
Joined:
Sep 2007
Posts:
25,108
Latest activity:
May 19, 2022
Log in to post a reply
Dec 16, 2021 06:32AM
moderators
wrote:
Aromatase Inhibitors versus Tamoxifen for Pre-Menopausal Women Diagnosed With Early-Stage, Hormone Receptor-Positive Disease
December 13, 2021
Dr. Jeremy Braybrooke, is a consultant medical oncologist and clinical lead for oncology at University Hospitals Bristol, as well as a senior clinical research fellow at the University of Oxford. Rosie Bradley is a medical statistician in the Clinical Trial Service Unit at the University of Oxford.
At the 2021 San Antonio Breast Cancer Symposium, Rosie presented the results of their meta-analysis of four studies looking at effectiveness of aromatase inhibitors compared to tamoxifen in pre-menopausal women diagnosed with early-stage, hormone receptor-positive disease.
Listen to the episode to hear them explain:
- the results of the study, showing that an aromatase inhibitor and ovarian suppression reduced recurrence risk more than tamoxifen, but didn't lead to better overall survival
- the side effects of aromatase inhibitors and tamoxifen
- how Dr. Braybrooke is advising his pre-menopausal patients diagnosed with early-stage, hormone receptor-positive disease
Running time: 14:19
Listen now or read the transcript.
M
moderators
Joined:
Sep 2007
Posts:
25,108
Latest activity:
May 19, 2022
Log in to post a reply
Dec 22, 2021 06:32AM
moderators
wrote:
Top Research Presented at the 2021 San Antonio Breast Cancer Symposium
December 21, 2021
Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical School.
The 2021 San Antonio Breast Cancer Symposium featured four days of presentations on the latest research on breast cancer. Dr. Tolaney joined us to discuss the research that is most immediately applicable to people who've been diagnosed with the disease.
Listen to the episode to hear Dr. Tolaney explain:
- results of an early study looking at how effective the experimental medicine datopotamab deruxtecan was in treating metastatic, triple-negative breast cancer
- a study comparing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) to Kadcyla (chemical name: T-DM1 or ad-trastuzumab emtansine) for metastatic, HER2-positive breast cancer that had spread to the brain
- the studies that she thinks are practice-changing
Running time: 10:00
Listen now or read the transcript.
M
moderators
Joined:
Sep 2007
Posts:
25,108
Latest activity:
May 19, 2022
Log in to post a reply
May 10, 2022 09:36AM
moderators
wrote:
Adolescent and Young Adult Breast Cancer
March 28, 2022
Rebecca Johnson, MD, discusses issues that are more challenging for younger women with breast cancer, reconstruction considerations for young women, and her advice for a newly diagnosed adolescent or young woman.
Listen to the episode to hear Dr. Johnson discuss:
* why the number of younger women diagnosed with breast cancer is going up, as well as the size of the increase
* issues that are more challenging for younger women with breast cancer reconstruction
* options for very young women
* her advice for a newly diagnosed adolescent or young woman
Running time: 52:45
Listen now or read the transcript.
M
moderators
Joined:
Sep 2007
Posts:
25,108
Latest activity:
May 19, 2022
Log in to post a reply
May 10, 2022 09:37AM
moderators
wrote:
Dating and Breast Cancer
April 29. 2022
In this episode, four different people explain their diagnoses and how they approached dating after breast cancer.
Running time: 47:03
Listen now or read the transcript.